Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2011-01-04
2011-01-04
Ouspenski, Ilia (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S387300
Reexamination Certificate
active
07863419
ABSTRACT:
The invention provides a method of producing aglycosylated Fc-containing polypeptides, such as antibodies, having desired effector function. The invention also provides aglycosylated antibodies produced according to the method as well as methods of using such antibodies as therapeutics.
REFERENCES:
patent: 5585097 (1996-12-01), Bolt et al.
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5714350 (1998-02-01), Co et al.
patent: 6165745 (2000-12-01), Ward et al.
patent: 6194551 (2001-02-01), Idusogie et al.
patent: 6218149 (2001-04-01), Morrison et al.
patent: 6277375 (2001-08-01), Ward
patent: 6284536 (2001-09-01), Morrison et al.
patent: 6350861 (2002-02-01), Co et al.
patent: 6528624 (2003-03-01), Idusogie et al.
patent: 6538124 (2003-03-01), Idusogie et al.
patent: 6720165 (2004-04-01), Nock et al.
patent: 6737056 (2004-05-01), Presta
patent: 6821505 (2004-11-01), Ward
patent: 6933368 (2005-08-01), Co et al.
patent: 6979553 (2005-12-01), Farinas et al.
patent: 7083784 (2006-08-01), Dall'Acqua et al.
patent: 7183387 (2007-02-01), Presta
patent: 7217797 (2007-05-01), Hinton et al.
patent: 7217798 (2007-05-01), Hinton et al.
patent: 7247302 (2007-07-01), Rosok et al.
patent: 7297775 (2007-11-01), Idusogie et al.
patent: 7317091 (2008-01-01), Lazar et al.
patent: 7332581 (2008-02-01), Presta
patent: 7335742 (2008-02-01), Presta
patent: 7351803 (2008-04-01), Johnson et al.
patent: 7355008 (2008-04-01), Stavenhagen et al.
patent: 2002/0131968 (2002-09-01), Waldmann et al.
patent: 2002/0147312 (2002-10-01), O'Keefe et al.
patent: 2002/0193573 (2002-12-01), Nock et al.
patent: 2003/0026692 (2003-02-01), Lutz
patent: 2003/0073164 (2003-04-01), Simmons et al.
patent: 2003/0158389 (2003-08-01), Idusogie et al.
patent: 2004/0006216 (2004-01-01), Waldmann et al.
patent: 2004/0010124 (2004-01-01), Johnson et al.
patent: 2004/0091957 (2004-05-01), Nock et al.
patent: 2004/0132101 (2004-07-01), Lazar et al.
patent: 2004/0191244 (2004-09-01), Presta
patent: 2004/0228856 (2004-11-01), Presta
patent: 2005/0054832 (2005-03-01), Lazar et al.
patent: 2005/0064514 (2005-03-01), Stavenhagen et al.
patent: 2005/0118174 (2005-06-01), Presta
patent: 2005/0170464 (2005-08-01), Simmons et al.
patent: 2005/0215768 (2005-09-01), Armour et al.
patent: 2005/0233382 (2005-10-01), Presta
patent: 2005/0244403 (2005-11-01), Lazar et al.
patent: 2006/0024298 (2006-02-01), Lazar et al.
patent: 2006/0160996 (2006-07-01), Lazar et al.
patent: 2006/0193856 (2006-08-01), Taylor et al.
patent: 2006/0275283 (2006-12-01), van Vlijmen et al.
patent: 2007/0092516 (2007-04-01), Waldmann et al.
patent: 2007/0202098 (2007-08-01), Lazar et al.
patent: 2007/0219133 (2007-09-01), Lazar et al.
patent: 2007/0224189 (2007-09-01), Lazar et al.
patent: 2007/0224192 (2007-09-01), Lazar et al.
patent: 2007/0237767 (2007-10-01), Lazar et al.
patent: 2007/0238665 (2007-10-01), Lazar et al.
patent: 2007/0243188 (2007-10-01), Lazar et al.
patent: 2007/0244303 (2007-10-01), Johnson et al.
patent: 2007/0248602 (2007-10-01), Lazar et al.
patent: 2007/0248603 (2007-10-01), Lazar et al.
patent: 2008/0050371 (2008-02-01), Johnson et al.
patent: 2008/0051563 (2008-02-01), Lazar et al.
patent: 2008/0206867 (2008-08-01), Desjarlais et al.
patent: 2009/0010920 (2009-01-01), Lazar et al.
patent: 2009/0068175 (2009-03-01), Lazar et al.
patent: 0255694 (1988-02-01), None
patent: WO-88/07089 (1988-09-01), None
patent: WO-89/07142 (1989-08-01), None
patent: WO-93/19196 (1993-09-01), None
patent: WO-93/22332 (1993-11-01), None
patent: WO-94/28027 (1994-12-01), None
patent: WO-94/29351 (1994-12-01), None
patent: WO-97/34631 (1997-09-01), None
patent: WO-98/05787 (1998-02-01), None
patent: WO-98/23289 (1998-06-01), None
patent: WO-98/47531 (1998-10-01), None
patent: WO-99/22764 (1999-05-01), None
patent: WO-99/51642 (1999-10-01), None
patent: WO-99/54484 (1999-10-01), None
patent: WO-99/58572 (1999-11-01), None
patent: WO-00/05268 (2000-02-01), None
patent: WO-00/42072 (2000-07-01), None
patent: WO-02/060919 (2002-08-01), None
patent: WO-02/062850 (2002-08-01), None
patent: WO-02/066514 (2002-08-01), None
patent: WO-02/079232 (2002-10-01), None
patent: WO-03/001870 (2003-01-01), None
patent: WO-03/026692 (2003-04-01), None
patent: WO-03/035835 (2003-05-01), None
patent: WO-03/059282 (2003-07-01), None
patent: WO-03/074679 (2003-09-01), None
patent: WO-03/101485 (2003-12-01), None
patent: WO-2004/029207 (2004-04-01), None
patent: WO-2004/035752 (2004-04-01), None
patent: WO-2004/063351 (2004-07-01), None
patent: WO-2004/063963 (2004-07-01), None
patent: WO-2004/074455 (2004-09-01), None
patent: WO-2004/074499 (2004-09-01), None
patent: WO-2004/099249 (2004-11-01), None
patent: WO-2005/003175 (2005-01-01), None
patent: WO-2005/018572 (2005-03-01), None
patent: WO-2005/040217 (2005-05-01), None
patent: WO-2005/056606 (2005-06-01), None
patent: WO-2005/056759 (2005-06-01), None
patent: WO-2005/070963 (2005-08-01), None
patent: WO-2005/077981 (2005-08-01), None
patent: WO-2005/115452 (2005-12-01), None
patent: WO-2006/019447 (2006-02-01), None
patent: WO-2006/020114 (2006-02-01), None
patent: WO-2006/031370 (2006-03-01), None
patent: WO-2006/033702 (2006-03-01), None
patent: WO-2007/059332 (2007-05-01), None
patent: 2007/100289 (2007-09-01), None
Attwood T. Science 2000; 290:471-47.
Skolnick et al., Trends in Biotech. 2000; 18(1):34-39.
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration for Application No. PCT/US2004/27476, dated Jan. 20, 2006.
Shields, Robert L. et al., “High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR,”The Journal of Biological Chemistry, vol. 276(9):6591-6604 (2001).
Sondermann, Peter et al., “The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex,”Nature, vol. 406:267-273 (2000).
Tao, Mi-Hua et al., “Studies of Aglycosylated Chimeric Mouse-Human IgG, Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region,”The Journal of Immunology, vol. 143(8):2595-2601 (1989).
Supplementary European Search Report for Application No. 04782045.1, dated May 7, 2009.
Armour, Kathryn L. et al., “Differential binding to human FcyRIIa and FcyRIIb receptors by human IgG wildtype and mutant antibodies,” Molecular Immunology, vol. 40:585-593 (2003).
Armour, Kathryn L. et al., “Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities,”Eur. J. Immunol., vol. 29:2613-2624 (1999).
Bastida-Corcuera, F.D. et al., “Differential complement activation by bovine IgG2 allotypes,”Veterinary Immunology and Immunopathology, vol. 71:115-123 (1999).
Boyd, P.N. et al., “The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of campath-1H,”Molecular Immunology, vol. 32(17/18):1311-1318 (1995).
Brekke, Ole Henrik et al., “Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis,”Eur. J. Immunol., vol. 24:2542-2547 (1994).
Burton, Dennis R., “Immunoglobulin G: Functional Sites,”Molecular Immunology, vol. 22(3):161-206 (1985).
Burton, D.R. et al., “The C1q receptor site on immunoglobulin G,”Nature, vol. 288:338-344 (1980).
Canfield, Stephen M. et al., “The Binding Affinity of Human IgG for its High Affinity Fc Receptor Is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region,”J. Exp. Med., vol. 173:1483-1491 (1991).
Caron, Philip C. et al., “Engineered Humanized Dimeric Forms of IgG Are More Effective Antibodies,”J. Exp. Med., vol. 176:1191-1195 (1992).
Chan, Lisa A. et al., “Variable region domain exchange in human IgGs promotes antibody complex formation with accompanying structural chang
Garber Ellen
Taylor Frederick R.
Biogen Idec MA Inc.
Lahive & Cockfield LLP
Ouspenski Ilia
Williams Megan E.
LandOfFree
Antibodies having altered effector function and methods for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies having altered effector function and methods for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies having altered effector function and methods for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2665806